Presentation by Stephen William, Chief Medical Officer, SomaLogic, USA

Promiscuous drug mechanisms in obesity, diabetes, and NASH; using proteomics to compare benefits across multiple organ systems

Share this article:

NASH is a local manifestation of systemic metabolic diease

New drug classes being developed in these fields can represent an embarrassment of riches, with potential benefits on cardiovascular outcomes, liver, kidney, and diabetic complications. Typically, these benefits have been discovered late in development, and each has required its own subsequent outcomes study. The existence of validated proteomic tests which can be applied in phase II to assess the potential benefits of new drugs in all of these systems within the same study could lead to improved choices around which outcomes studies to pursue.